Fmoc-Asp(ODmab)-OH,
269066-08-2,
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((4-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)amino)benzyl)oxy)-4-oxobutanoic acid,
DTXSID70681027,
C39H42N2O8,
MFCD00797875,
AKOS016003534,
ZINC150339255,
CS-W007108,
FT-0693451,
066F082,
J-016598,
(2S)-4-[(4-{[1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}phenyl)methoxy]-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-oxobutanoic acid (non-preferred name),
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((4-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)amino)benzyl)oxy)-4-oxobu,
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(4-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutylamino)benzyloxy)-4-oxobutanoic acid,
Fmoc-L-aspartic acid beta-4-[N-{1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl}amino]benzyl ester,
N-(9H-Fluorene-9-ylmethoxycarbonyl)-L-aspartic acid 4-[4-[[1-(2,6-dioxo-4,4-dimethylcyclohexylidene)-3-methylbutyl]amino]benzyl] ester,
V0015,